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ABSTRACT
Familial cold autoinﬂammatory syndrome, Muckle-Wells
syndrome (MWS), and chronic, infantile, neurological,
cutaneous and articular (CINCA) syndrome are
dominantly inherited autoinﬂammatory diseases
associated to gain-of-function NLRP3 mutations and
included in the cryopyrin-associated periodic syndromes
(CAPS). A variable degree of somatic NLRP3 mosaicism
has been detected in ≈35% of patients with CINCA.
However, no data are currently available regarding the
relevance of this mechanism in other CAPS phenotypes.
Objective To evaluate somatic NLRP3 mosaicism as
the disease-causing mechanism in patients with clinical
CAPS phenotypes other than CINCA and NLRP3
mutation-negative.
Methods NLRP3 analyses were performed by Sanger
sequencing and by massively parallel sequencing.
Apoptosis-associated Speck-like protein containing a
CARD (ASC)-dependent nuclear factor kappa-light chain-
enhancer of activated B cells (NF-κB) activation and
transfection-induced THP-1 cell death assays determined
the functional consequences of the detected variants.
Results A variable degree (5.5–34.9%) of somatic
NLRP3 mosaicism was detected in 12.5% of enrolled
patients, all of them with a MWS phenotype. Six
different missense variants, three novel (p.D303A,
p.K355T and p.L411F), were identiﬁed. Bioinformatics
and functional analyses conﬁrmed that they were
disease-causing, gain-of-function NLRP3 mutations.
All patients treated with anti-interleukin1 drugs showed
long-lasting positive responses.
Conclusions We herein show somatic NLRP3
mosaicism underlying MWS, probably representing a
shared genetic mechanism in CAPS not restricted to
CINCA syndrome. The data here described allowed
deﬁnitive diagnoses of these patients, which had serious
implications for gaining access to anti-interleukin
1 treatments under legal indication and for genetic
counselling. The detection of somatic mosaicism is
difﬁcult when using conventional methods. Potential
candidates should beneﬁt from the use of modern
genetic tools.
Cryopyrin-associated periodic syndromes (CAPS) are a
group of autoinﬂammatory diseases that include famil-
ial cold autoinﬂammatory syndrome, Muckle-Wells
syndrome (MWS), and chronic, infantile, neurological,
cutaneous and articular (CINCA) syndrome, also
known as neonatal-onset multisystem inﬂammatory
disease (NOMID).1 Some clinical features are shared
by almost all CAPS phenotypes (ie, onset during child-
hood, an urticaria-like skin rash) whereas others are
restricted to certain phenotypes (ie, serum amyloid A
protein (AA) amyloidosis in MWS, destructive arthro-
pathy in CINCA-NOMID).1 CAPS are caused by dom-
inantly inherited or de novo NLRP3 mutations.2–4
This gene encodes for cryopyrin, a component of one
of the cytosolic complexes named inﬂammasomes that
generate the active form of interleukin 1ß (IL-1ß).5
Previous studies showed a gain-of-function behaviour
for those NLRP3 mutations associated with CAPS
because they provoke an uncontrolled IL-1ß overpro-
duction, representing the basis from which to treat
these patients with anti-IL-1 drugs.3 6 Genetic hetero-
geneity was suggested in CINCA-NOMID because
only ≈55% of patients wasNLRP3mutation-positive.3
4 The use of novel genetic methods recently detected
somatic NLRP3 mosaicism in ≈35% of patients with
CINCA-NOMID.7 8 However, no data are currently
available about the role of this genetic mechanism in
other CAPS phenotypes because genetic heterogeneity
has hitherto been scarcely reported in previous studies.
We herein show the causal role of somatic
NLRP3 mosaicism in patients with MWS, in whom
previous studies did not detect NLRP3 mutations,
suggesting that this genetic mechanism is shared
among the different CAPS phenotypes.
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PATIENTS AND METHODS
Patients
For this study we enrolled patients with a clinical suspicion of
CAPS, with a phenotype of MWS and overlapping syndromes,
and NLRP3 mutation-negative in previous studies. The clinical
inclusion criteria were the presence of an urticaria-like skin rash
and at least one of the following symptoms: recurrent fever, recur-
rent arthritis, recurrent aseptic meningitis, sensorineural deafness
or AA amyloidosis (see online supplementary table S1 for details).
All patients with a CINCA-NOMID phenotype were excluded.
The patients’ data were collected by direct interviews and chart
reviews. Written informed consent from patients (or patients’
parents if younger than 18-years-old) was obtained at each institu-
tion. The ethics committees of Hospital Clinic, Barcelona and the
Graduate School of Medicine, Kyoto University approved this
study, which was conducted in accordance with the Helsinki
Declaration.
NLRP3 analyses
These analyses were performed in the Graduate School of
Medicine, Kyoto University or in the Hospital Clínic, Barcelona.
Genomic DNA was obtained from whole peripheral blood using
QIAmp DNA Blood Mini Kit (QIAgen, Germany). For Sanger
sequencing all exons of NLRP3 gene were ampliﬁed by PCR using
the primers and conditions previously described.2 The PCR ampli-
cons were puriﬁed with Illustra ExoStar 1-Step kit (GE
Healthcare, USA), bidirectional ﬂuorescence sequencing using ABI
BigDye Terminator V.3.1 Cycle Sequencing Kit (Applied
Biosystems, USA) and run on an automated ABI 3730XL DNA
analyzer. For massively parallel DNA sequencing, all exons of
NLRP3 gene were ampliﬁed as previously described.8 Library
preparation and emulsion PCR were performed according to man-
ufacturer’s instructions. All sequencing runs were performed on
the GS Junior 454 Sequencer using the GS Junior Titanium
Sequencing kits (Roche, Switzerland). The obtained sequences
were analysed using the Amplicon Variant Analyzer software.
Bioinformatics analyses
In silico sequence analyses were performed using two different
algorithms. The Sorting Intolerant from Tolerant is a sequence
homology based tool that predicts whether the amino acid sub-
stitution is or is not probably damaging by reporting a score.
The PolyPhen-2 is a tool for prediction of the possible impact
of an amino acid substitution on the structure and function of a
protein, and qualitatively appraised as benign, possibly dam-
aging or probably damaging.9 10
Functional studies
The functional consequences of the novel NLRP3 variants were
evaluated in two in vitro assays.11 Wild type and mutant NLRP3
cDNA, obtained by mutagenesis PCR, were subcloned into the
expression vectors pEF-BOSEX and pcDNA5/TO (Invitrogen,
USA). The Apoptosis-associated Speck-like protein containing a
CARD (ASC)-dependent nuclear factor kappa-light chain-enhan-
cer of activated B cells (NF-κB) activation was evaluated using a
dual-luciferase reporter assay in HEK293FT cells transfected
with NLRP3-pEF-BOSEX plasmids with a NF-kB reporter con-
struct (pNF-kB-luc, BD Biosciences) and an internal control
construct (pRLTK, Toyo Ink) in the presence or absence of
ASC-expression plasmid. To evaluate the necrosis-like cell death,
the THP-1 cell line (a human monocytic cell line derived from a
patient with acute monocytic leukemia) was transfected with
green ﬂuorescent protein (GFP)-tagged NLRP3-pcDNA5/TO
plasmids. After 4 h, cells were stained with 7-aminoactinomycin
D and cell death of GFP positive cell was analysed by FACS
Caliber (Becton-Dickinson).
Statistical analyses
Continuous variables are presented as the mean±SD or as the
median and IQR, while categorical variables are presented as
numbers, ratios and/or percentages. To detect potential differences
among patients with germline mutations and with somatic muta-
tions, the Mann-Whitney U test was used for continuous variables
and Fisher’s exact test was used for categorical variables.
RESULTS
Genetic analyses
Fifty-six patients (23 Japanese and 33 Spanish) who fulﬁlled the
inclusion criteria were enrolled. Sanger sequencing of the
NLRP3 gene did not identify mutations in any patients.
However, small peaks with reduced signal intensities compared
with controls were detected in two patients: the A-to-C trans-
version at c.908 position in Patient 1 and the A-to-G transition
at c.1000 position in Patient 2, which encode for the p.
Asp303Ala and p.Ile334Val cryopyrin variants, respectively
(ﬁgure 1A and table 1). Massively parallel DNA sequencing was
performed in all patients and revealed somatic NLRP3 mosai-
cism in seven patients (7/56; 12.5%). Six different nucleotide
changes, all of them located in the exon 3, were detected, and
their frequency varied notably among patients, ranging from
5.5% to 34.9% (table 1). All NLRP3 variants encode for non-
synonymous amino acid changes, three of them being novel (p.
Asp303Ala, p.Lys355Thr and p.Leu411Phe) and the remainder
already described (p.Ile334Val, p.Phe523Leu and p.Glu567Lys)
(ﬁgure 1B). In Patient 4 the frequency of the mutated NLRP3
allele remained identical in blood samples obtained over an
8-year period (table 1).
Bioinformatics and functional analyses
All missense NLRP3 variants were predicted to be possibly or
probably damaging to cryopyrin structure and/or function accord-
ing to at least one of the two algorithms employed, with the only
exception of p.Glu567Lys variant (table 1). Interestingly, this
NLRP3 variant was twice detected in the unrelated patients with
somatic mosaicism, and has also been reported in other patients
with CAPS, reasonably supporting its pathogenic effect.7 11 We
did not ﬁnd any of the detected NLRP3 variants in two groups of
ethnically matched healthy individuals ( Japanese controls n: 200
chromosomes; Spanish controls n: 500 chromosomes) nor in the
database National Center for Biotechnology Information (NCBI)
single nucleotide polymorphism database (dbSNP) Build 137
(table 1), reasonably ruling out that they could be rare gene
polymorphisms.
Finally we evaluated their functional consequences by two dif-
ferent in vitro assays. The results showed that all NLRP3 variants
induced ASC-dependent NF-κB activation (ﬁgure 1C) and
necrosis-like programmed cell death of THP-1 cell line (ﬁgure
1D) at a similar or higher level than those induced by other well-
known disease-causing mutations (p.Arg260Trp, p.Asp303Asn
and p.Tyr570Cys). Altogether, these data clearly support a patho-
genic effect for all NLRP3 mutations detected as somatic muta-
tions in the enrolled patients.
Clinical features of patients with somatic NLRP3 mosaicism
At the time of inclusion in the study, the clinical diagnosis of
patients with somatic NLRP3 mosaicism was compatible with
MWS. Neither consanguinity nor familial history of the disease
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was reported in any of them. The inﬂammatory disease started
during their infancy or childhood (median: 4 years; IQR: 1.3–
9.0 years), with an urticaria-like skin rash and a marked inﬂam-
matory acute response as the main features at that time
(see table 2 for clinical details at the disease onset).
All patients referred to the chronic course of their disease,
with variable disease evolution (median: 20 years; IQR: 12–26
years). During this time, recurrent arthritis (6/7; 85.7%), head-
ache (5/7; 71.4%) and recurrent conjunctivitis (4/7; 57.1%)
mainly added to those features detected at the disease onset.
None of these patients developed AA amyloidosis, whereas ﬁve
of them (71.4%) developed progressive bilateral sensorineural
deafness (see table 3 for a detailed summary of clinical features
detected during the course of the disease).
Outcome of anti-IL-1 blockade
Five patients with somatic NLRP3 mosaicism were treated with
anti-IL-1 drugs. Only Patient 5 was treated with anakinra
(100 mg/24 h subcutaneous for a duration of 20 months). Three
patients only received canakinumab: Patient 2 (150 mg/8 weeks
subcutaneous for a duration of 13 months), Patient 3 (2 mg/kg/
8 weeks subcutaneous for a duration of 16 months) and Patient
6 (initial dose of 150 mg/4 weeks, subsequently increased up to
300 mg/4 weeks, for a duration of 14 months). Patient 7 was
ﬁrst treated with anakinra (1 mg/kg/24 h subcutaneous for a dur-
ation of 24 months) and subsequently switched to canakinumab
(150 mg/8 weeks subcutaneous for a duration of 14 months). All
patients showed a marked and sustained improvement while
treated with anti-IL-1 drugs, with a complete remission of
urticaria-like skin rash (5/5), fever (3/3), conjunctivitis (2/2) and
aseptic meningitis (1/1), and marked beneﬁts for arthritis (com-
plete response in 75%) and headache (complete response in
75%, and marked improvement in 25%). Inversely, IL-1 block-
ade did not improve the sensorineural deafness (0/4). The clin-
ical improvement was associated with sustained reductions of
erythrocyte sedimentation rate and C reactive protein level, and
normalisation of white blood cell, neutrophil and platelets
counts, and haemoglobin level (see ﬁgure 2 for details).
Comparative phenotype analyses
To identify potential clinical differences among patients with
germline or with somatic NLRP3 mutations two cohorts of
Figure 1 (A) Sense (upper rows) and antisense (bottom rows) chromatograms from four patients with somatic NLRP3 mosaicism and controls
obtained by Sanger sequencing using genomic DNA extracted from whole blood. The black arrows show the NLRP3 positions where the somatic
mutations were detected. The percentage in the upper panels represents the frequency of the mosaicism obtained by massively parallel DNA
sequencing in each patient. The red arrows indicate the c.1231 C>T NLRP3 polymorphism (rs#148478875). (B) Structural organisation of cryopyrin.
Above the protein structure are indicated all missense cryopyrin variants that have been detected as somatic mutations in patients with chronic,
infantile, neurological, cutaneous and articular (CINCA)-neonatal-onset multisystem inﬂammatory disease (NOMID) in previous reports, and those
below the protein structure are the missense variants detected as somatic mutations in the present study. (C) ASC-dependent NF-kB activation and
(D) necrotic THP-1 cell death, induced by the detected NLRP3 mutations. Values are the mean±SD of triplicate experiments, and data are
representative of two independent experiments. AS, antisense; ASC, Apoptosis-associated Speck-like protein containing a CARD; C, control; LRR,
leucine-rich repeat; mock, vector without NLRP3; MWS, Muckle-Wells syndrome; NACHT, a family of NTPases that originally included the NAIP,
CIITA, HETE-E and TP-1 proteins; NF-kB, nuclear factor kappa-light chain-enhancer of activated B cells; None, nothing transfected; Pt, patient;
PyD, pyrin domain; S, sense; WT, wild type NLRP3.
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patients with MWS were compared. The group of patients with
MWS with somatic NLRP3 mosaicism included the seven
patients described here whereas the cohort of patients with
MWS with germline mutations included 41 patients (13
Japanese and 28 Spanish) from our databases. In this last group
the germline status was established by means of pedigree ana-
lyses and/or by massively parallel sequencing. As expected, the
familial history of the disease was a signiﬁcant variable between
the two groups. No signiﬁcant differences were detected among
the main clinical features (fever, urticaria-like rash, joint, neuro-
logical and ocular involvements, and deafness) despite their vari-
able frequency in each group (see table 4 for details). However,
patients with somatic NLRP3 mosaicism seemed to have late
onsets of the disease and of the sensorineural deafness, an
increased incidence of arthritis and a reduced risk of developing
AA amyloidosis, when compared with patients with germline
mutations.
DISCUSSION
CINCA-NOMID syndrome represents the severest CAPS pheno-
type, and is usually a consequence of de novo NLRP3 mutations.
Recent works have established its genetic basis, with ≈55% of
patients carrying germline NLRP3 mutations and ≈35% carrying
somatic NLRP3 mosaicism.3–4 7 11–16 However, no studies
addressing the presence of somatic NLRP3 mosaicism have been
undertaken in other CAPS phenotypes because genetic hetero-
geneity has been poorly described in them, with only ﬁve
reported patients with NLRP3 mutation-negative MWS.17–19
This scenario prompted us to hypothesise that somatic NLRP3
mosaicism might be an underlying genetic mechanism in patients
with other CAPS phenotypes. For this proposal two ethnically
different cohorts of candidates were screened, and 12.5% of
them (7/56) carried variable degree of somatic NLRP3 mosaicism
in peripheral blood. Additional evidences, as shown here, deﬁni-
tively support that the detected NLRP3 variants are pathogenic
Table 1 Summary of genetic data of patients with somatic NLRP3 mosaicism
Pt
(Country) Phenotype
Nucleotide
exchange*
Amino acid
exchange
Massively parallel DNA
sequencing Bioinformatics analyses
Reference
Analysed relatives
Mutated allele
frequency Coverage SIFT PolyPhen-2
Population
genetics† Kinship Results
1 (Spain) MWS c.908 A>C p.D303A 31.3%‡ 622×‡ Damaging Probably
damaging
Absent Present
Study
n.d. n.d.
2 ( Japan) MWS c.1000 A>G p.I334V 34.9%‡ 1060×‡ Damaging Benign Absent 12 Father Negative§
Mother Negative§
3 ( Japan) MWS c.1064 A>C p.K355T 20.2%‡ 100×‡ Tolerated Probably
damaging
Absent Present
Study
n.d. n.d.
4¶ (Spain) MWS c.[1231 C>T;
1233 G>T]
p.L411F 14.4%‡ 590×‡ Tolerated Possibly
damaging
Absent Present
Study
Mother Negative§
4** (Spain) MWS c.[1231 C>T;
1233 G>T]
p.L411F 15.6%‡ 870×‡ Tolerated Possibly
damaging
Absent Present
Study
Mother Negative§
5 (Spain) MWS c.1569 C>A p.F523L 8.7%†† 569×†† Tolerated Possibly
damaging
Absent 3 Daughter Negative§
6 ( Japan) MWS c.1699 G>A p.E567K 5.6%‡ 1211×‡ Tolerated Benign Absent 11 n.d. n.d.
7 ( Japan) MWS c.1699 G>A p.E567K 5.5%‡ 724×‡ Tolerated Benign Absent 11 n.d. n.d.
*NCBI Reference Sequence NM_001243133.1.
†Data of population genetics obtained from NCBI dbSNP Build 137.
‡Mean of two independent experiments.
§Analyses performed by Sanger sequencing.
¶Blood sample collected in 2002.
**Blood sample collected in 2009.
††Mean of four independent experiments.
MWS, Muckle-Wells syndrome; n.d., not done; Pt, patient; SIFT, Sorting Intolerant from Tolerant.
Table 2 Summary of clinical features of patients with somatic NLRP3 mosaicism at the onset of the disease
Pt
Age at disease
onset
Cold-exposure
trigger
Urticaria-like skin
rash Fever
Joint
involvement
CNS
involvement
Acute inflammatory
response* First diagnoses
1 18 years – Yes Yes Arthralgias – Yes
2 2 years – Yes – Arthralgias – Yes JIA
3 1 week – Yes – – – Yes Chronic urticaria,
So-JIA
4 14 years – Yes Yes – – Yes Erythema nodosa
5 4 years Yes Yes Yes Arthralgias – Yes
6 4 years Yes Yes Yes† Oligoarthritis – Yes Oligo-JIA
7 7 months - Yes Yes Oligoarthritis – n.a. So-JIA, TRAPS
*Defined by increased values of white blood cells (normal range 4.00–11.00×103/dL), circulating neutrophils (normal range 45–75%), platelets (normal range 130–400×103/dL),
C reactive protein (normal range <1 mg/dL) and/or erythrocyte sedimentation rate (normal <10 mm/h).
†Low-grade fever.
–, absent; CNS, central nervous system; JIA, juvenile idiopathic arthritis; n.a., not available; Pt, Patient; So-JIA, systemic-onset juvenile idiopathic arthritis; TRAPS,
TNF receptor-associated periodic syndrome.
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and include their absence in panels of ethnically matched con-
trols and in a database of genomic diversity, in silico analyses that
predict their damaging effect for the function and/or structure of
cryopyrin, and in vitro functional studies that clearly showed its
gain-of-function behaviour. Taken together these evidences
support that somatic NLRP3 mosaicism is a genetic mechanism
shared by different CAPS phenotypes, and it is not restricted to
CINCA-NOMID syndrome.
Among NLRP3 mutations detected 50% (3/6) were novel,
representing an unexpected high proportion for a small cohort.
Taking into account their consequences on the cryopyrin func-
tion it is conceivable to hypothesise that, in germline status,
they could be incompatible with life. We have also found a
marked variability in the degree of somatic mosaicism among
patients, which may have important consequences. For diagnos-
tic purposes the level of somatic mosaicism could be the deter-
mining factor in achieving a deﬁnitive genetic diagnosis. Those
patients with mosaicism around, or higher than, 15% will prob-
ably be detected in conventional studies using Sanger’s method
by means of careful analyses, as we have shown in the patients’
chromatograms. However, those patients with frequencies of
less than 15% are probably missed by Sanger sequencing and
will only be detected by using new technologies that are not cur-
rently widely available. The differences of disease severity
observed among patients with somatic mosaicism, including
those from this study and those from previous reports, could be
explained by different and cumulative factors, which probably
cannot be independently analysed. These factors might include,
at least, the type of amino acid exchange, its location in the
cryopyrin, its functional consequence in the normal cryopyrin
function, and the degree and tissue distribution of somatic
mosaicism. We must also note that all known somatic NLRP3
mutations seem to be located in some few amino acid residues
(303, 355, 567) or in small regions of cryopyrin (303–307,
433–439 and 566–570), probably representing hot spots for
these types of mutations. Consequently these regions should be
carefully analysed when using Sanger sequencing to identify
potential carriers of somatic mosaicism.
All patients with somatic NLRP3 mosaicism were sporadic
patients, with no affected relatives, which is notably different
from patients with germline mutations (positive familial history
in 65.9%). Their main clinical features were compatible with a
MWS phenotype and similar to those previously described in
patients with germline mutations, with the potential exceptions
of a reduced incidence of AA amyloidosis, an increased inci-
dence of recurrent arthritis, and slightly older ages at the disease
onset and also at onset of sensorineural deafness. It is interesting
to note that most patients (4/7; 57.1%) were misdiagnosed as
having juvenile idiopathic arthritis when the disease started, a
similar misdiagnosis previously reported in different inherited
autoinﬂammatory diseases.20–23 Despite the evidence shown
here, the actual frequency of somatic NLRP3 mosaicism is
unknown and probably underestimated. In our study a potential
bias in the selection of patients could exist because they were
selected on the basis of the presence of an urticaria-like skin
rash associated with other symptoms. Recent studies have
described atypical CAPS presentations in patients with germline
NLRP3 mutations in whom urticaria-like skin rash was nearly
absent.24 25 These data suggest that clinical diversity of CAPS is
probably wider than previously described and further studies
are necessary to delineate the proﬁle of potential candidates to
carry somatic NLRP3 mosaicism.
The evidence obtained may have serious implications for
patients, especially with regards to treatment and genetic
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Figure 2 Laboratory values obtained in the ﬁve patients treated with different anti-interleukin 1 drugs. Patient’s graphics were ordered as follows:
First, those graphics from the patient who only received treatment with anakinra (Pt 5), followed by those from patients who only received
treatment with canakinumab (Pt 2, 3 and 6) and ﬁnally those from the patient who received both treatments (Pt 7). Vertical bars represent the
mean±SD of values obtained during treatment periods. Horizontal discontinued lines represent the upper limit of the normal range, with the only
exception of the haemoglobin box, in which this line represents the lower limit of the normal range. CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; PMN, polymorphonuclears; WBC, white blood cell count.
Table 4 Comparison of main clinical data of patients carrying germline versus somatic NLRP3 mutations
Clinical features
Patients with germline NLRP3
mutations (n:41)
Patients with somatic NLRP3
mutations (n:7) p Value
Age at disease onset (years)—median (IQR) 0.5 (0.0–4.4) 4.0 (1.3–9.0) n.s. (p=0.223)
Delay of diagnosis (years)—median (IQR) 33.0 (10–49) 20 (12–26) n.s. (p=0.416)
Presence of familial history of the disease (%) 65.9 0 p=0.002
Cold exposure as disease triggering factor (%) 36.6 28.6 n.s. (p=1.000)
Fever (%) 63.4 71.4 n.s. (p=1.000)
Urticaria-like skin rash (%) 87.8 100 n.s. (p=1.000)
Joint involvement
Arthralgias (%) 80.5 85.7 n.s. (p=1.000)
Arthritis (%) 53.7 85.7 n.s. (p=0.214)
Neurological involvement
Headache (%) 56.1 71.4 n.s. (p=0.683)
Aseptic meningitis (%) 29.3 14.3 n.s. (p=0.656)
Papilloedema (%) 12.2 0 n.s. (p=1.000)
Ocular involvement
Conjunctivitis (%) 61.0 57.1 n.s. (p=1.000)
Uveitis (%) 17.1 0 n.s. (p=0.573)
Sensorineural deafness (%) 68.3 71.4 n.s. (p=1.000)
Age at onset of deafness (years)—median (IQR) 7.0 (5.5–11) 13.0 (7–38) n.s. (p=0.210)
AA amyloidosis (%) 17.1 0 n.s. (p=0.573)
Patients with germline mutations were carriers of one of the next NLRP3 mutations: p.R170S (c.508 C>A), p.R260W (c.778 C>T), p.V262A (c.785 T>C), p.D303N (c.907 G>A), p.H312P
(c.935 A>C), p.T348M (c.1043 C>T), p.A439T (c.1315 G>A), p.A439V (c.1316 C>T), p.F443L (c.1329 C>G), p.E567A (c.1700 A>C) and p.Y859C (c.2576 A>G).
AA, serum amyloid A protein; n.s., not significant differences.
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counselling. The outcome of IL-1 blockade in patients with
somatic NLRP3 mosaicism was nearly identical to those
reported in patients with germline mutations.26 27 The only
symptom that did not improve with IL-1 blockade was the sen-
sorineural deafness. In this regard, apparently contradictory
responses have been reported, with improvement or amelior-
ation in some patients and no response in others.14 17 28–30 It
has been suggested that the time of evolution of deafness previ-
ous to starting anti-IL-1 drugs could be a determining factor for
the type of response, but probably additional and unknown
factors could also play a role in this particular manifestation. We
have also observed a notable delay in gaining access to anti-IL-1
drugs with respect to the disease onset (median: 20 years; IQR:
12–26 years), because these treatments were administered under
legal indication once the deﬁnitive CAPS diagnosis was estab-
lished by means of the identiﬁcation of somatic NLRP3 mosai-
cism. Taking into account the excellent response observed to
IL-1 blockade, it is reasonable to hypothesise that if this was
started earlier it should have provoked the non-appearance of
some severe complications such as deafness.
For an appropriate genetic counselling the scenario is
extremely different in patients with CAPS with germline or with
somatic mutations. In the case of germline mutations, the risk of
transmission to future pregnancies is 50%. Inversely, the predic-
tion of the risk of transmission in cases of somatic mosaicism is
more complex, because it may vary in the different tissues, it is
not usually determined in gonadal tissues, and its detection
probably requires new sensitive genetic methods that are not
widely available. The vertical transmission of a somatic mutation
is an extremely rare event, with only one case recently described
in MWS.31 Consequently, this possibility should be considered
during the genetic counselling of these patients, although one of
the main messages to patients is that its probability remains low.
We show that somatic NLRP3 mosaicism underlies MWS and
is probably a shared genetic mechanism in different CAPS phe-
notypes, and not restricted to CINCA/NOMID syndrome. Its
detection was achieved by using massively parallel sequencing,
and functional studies conﬁrmed the gain-of-function behaviour
of the detected variants. The detection of somatic mosaicism
has had serious clinical implications for patients, including
access to treatment under legal indication, adequate follow-up
and ensuring appropriate genetic counselling. Further studies
are necessary to delineate the clinical phenotype of candidates
to looking for somatic mosaicism, in which new sensitive
genetic technologies should be used.
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